Targeting Wnt/β-catenin Pathway in Hepatocellular Carcinoma Treatment

Valery Vilchez  
*University of Kentucky*, vvi223@uky.edu

Lilia M. Turcios  
*University of Kentucky*, lturc2@uky.edu

Francesc Marti  
*University of Kentucky*, francesc.marti@uky.edu

Roberto Gedaly  
*University of Kentucky*, roberto.gedaly@uky.edu

Follow this and additional works at: [https://uknowledge.uky.edu/surgery_facpub](https://uknowledge.uky.edu/surgery_facpub)

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation

Vilchez, Valery; Turcios, Lilia M.; Marti, Francesc; and Gedaly, Roberto, "Targeting Wnt/β-catenin Pathway in Hepatocellular Carcinoma Treatment" (2016). *Surgery Faculty Publications*. 27.  
[https://uknowledge.uky.edu/surgery_facpub/27](https://uknowledge.uky.edu/surgery_facpub/27)

©Part of the Cancer Biology Commons, Oncology Commons, and the Surgery Commons

This Article is brought to you for free and open access by the Surgery at UKnowledge. It has been accepted for inclusion in Surgery Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Targeting Wnt/β-catenin Pathway in Hepatocellular Carcinoma Treatment

Digital Object Identifier (DOI)
https://doi.org/10.3748/wjg.v22.i2.823

Notes/Citation Information
Published in World Journal of Gastroenterology, v. 22, issue 2, p. 823-832.

© 2016 Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

This article is available at UKnowledge: https://uknowledge.uky.edu/surgery_facpub/27
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment

Valery Vilchez, Lilia Turcios, Francesc Marti, Roberto Gedaly

Valery Vilchez, Lilia Turcios, Francesc Marti, Roberto Gedaly, Department of Surgery, Division of Transplantation, College of Medicine, University of Kentucky, Lexington, KY 40536-0284, United States

Author contributions: Vilchez V, Turcios L, Marti F and Gedaly R contributed equally in developing the concept, writing and correcting this manuscript.

Conflict-of-interest statement: Authors declare no conflict of interest for this article.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Roberto Gedaly, MD, Department of Surgery, Division of Transplantation, College of Medicine, University of Kentucky, Lexington, KY 40536-0284, United States. rgeda2@uky.edu
Telephone: +1-859-3234661
Fax: +1-859-2573644

Received: October 27, 2015
Peer-review started: October 31, 2015
First decision: November 13, 2015
Revised: December 5, 2015
Accepted: December 19, 2015
Article in press: December 21, 2015
Published online: January 14, 2016

Abstract

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death worldwide. Liver cancer is generally related to hepatitis B or C infection and cirrhosis. Usually, patients with HCC are asymptomatic and are diagnosed at late stages when surgical treatment is no longer suitable. Limited treatment options for patients with advanced HCC are a major concern. Therefore, there is an urge for finding novel therapies to treat HCC. Liver cancer is highly heterogeneous and involved deregulation of several signaling pathways. Wnt/β-catenin pathway is frequently upregulated in HCC and it is implicated in maintenance of tumor initiating cells, drug resistance, tumor progression, and metastasis. A great effort in developing selective drugs to target components of the β-catenin pathway with anticancer activity is underway but only a few of them have reached phase I clinical trials. We aim to review the role of β-catenin pathway on hepatocarcinogenesis and liver cancer stem cell maintenance. We also evaluated the use of small molecules targeting the Wnt/β-catenin pathway with potential application for treatment of HCC.

Key words: Hepatocellular carcinoma; Wnt/β-catenin pathway; Liver cancer stem cells; Molecular therapy

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Several signaling pathways have been described to be deregulated in hepatocellular carcinoma (HCC). There are limited treatment options currently available in advanced liver cancer. Wnt/β-catenin pathway is frequently upregulated and has emerged as an alternative target in HCC. Our group has studied the role of β-catenin inhibition alone and in combination in HCC treatment. In this review we summarized the existing literature on the importance of Wnt/β-catenin pathway on hepatocarcinogenesis, tumor progression, relationship with liver stem cells and cancer therapeutics.
pathway in hepatocellular carcinoma treatment. *World J Gastroenterol* 2016; 22(2): 823-832. Available from: URL: http://www.wjgnet.com/1007-9327/full/v22/i2/823.htm DOI: http://dx.doi.org/10.3748/wjg.v22.i2.823

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and the third most common cause of cancer-related deaths worldwide[1]. Its prevalence differs greatly by geographical location reflecting variations in the main risk factors. Most cases of HCC (80%) arise in the Asian-Pacific and sub-Saharan African regions where the prevailing risk factor is chronic hepatitis B virus (HBV) infection. In Western countries, the incidence has been rapidly increasing due to infection with hepatitis C virus (HCV) and alcohol[2].

Early HCC is asymptomatic and a majority of the patients are diagnosed when the disease is advanced and they are no longer candidates for surgical curative therapy. Resection remains the treatment of choice for patients with well-preserved liver function; however, it is still associated with a high risk of post-operative complications and tumor recurrence. Among patients who have underlying cirrhosis, liver transplantation is considered the best therapeutic option in selected candidates but its use is limited by the shortage of potential donors. Other alternative treatments for HCC include radio-frequency ablation, microwave ablation, transcatheter arterial chemoembolization, radio embolization, and molecular targeted therapies/chemotherapy[2,3].

In past decades, there have been significant efforts from different groups to develop compounds to treat HCC. Sorafenib, a multikinase inhibitor, has been found to be active against HCC in several pre-clinical and clinical studies, slowing tumor progression and improving survival in patients with advanced HCC. It is the drug of choice in patients with advanced HCC that are unsuitable for other types of surgical, ablative and embolization interventions[4]. Tumor recurrence remains a strong limitation to any of the HCC treatments, hence understanding the molecular biology of HCC is crucial for the development of novel therapies.

Numerous signaling pathways have been found to be deregulated in HCC including the Ras/Raf/MAPK, PI3K/mTOR, Notch, HGF/c-MET, IGF, VEGF, PDGF, and Wnt/β-catenin pathway[4-6]. Wnt signaling is involved in several physiological and physiopathological processes during embryonic development and carcinogenesis[7,8]. Wnt/β-catenin signaling plays a critical role in liver development, liver regeneration and liver zonation which is required for spatial separation of the diverse metabolic functions performed in the liver[7]. Aberrant activation of this signaling pathway has been found in several tumors from different origin. In HCC, β-catenin accumulation has been observed in about 10%-50% of tumors, and has been correlated with tumor progression and poor prognosis[9-11]. Based on these observations, interfering with the Wnt/β-catenin pathway might be a tempting target for liver cancer therapy. Several compounds have been developed to target this pathway and their potential in clinical trials is under study. Our group recently investigated the ability of FH-535, a dual inhibitor of β-catenin pathway and the peroxisome proliferator-activated receptor (PPAR), to inhibit HCC and liver cancer stem cells (LCSC) growth *in vitro* and its effectivity in a combination therapy with sorafenib[12,13].

The aim of this article is to review the literature on the role of Wnt/β-catenin signaling pathway as a potential molecular-targeted therapy in HCC.

**WNT/β-CATENIN SIGNALING PATHWAY**

The Wnt pathway diversifies into two main branches, canonical or β-catenin-dependent and non-canonical or β-catenin-independent. The canonical pathway involves three complexes: the ligand/receptor cell membrane complex, the cytosol β-catenin destruction complex, and the nuclear β-catenin/TCF/LEF transcription complex[14,15]. Wnt protein can bind to the heterodimeric receptor complex of a frizzled (Fz) and a single transmembrane lipoprotein receptor-related protein (LPR) 5 or 6 co-receptors. When Fz/LRP receptors are not engaged, β-catenin is clustered, phosphorylated and ubiquitin-labeled by the multiprotein “destruction complex” that includes the tumor suppressors axin and adenomatous polyposis coli (APC), the Ser/Thr kinases glycogen synthase kinase 3 (GSK-3) and casein kinase 1 (CK1), the protein phosphatase 2A, and the E3-ubiquitin ligase β-TrCP (Figure 1, right panel). Once phosphorylated, β-catenin is ubiquitinated and destroyed by the proteasome. Therefore, the destruction complex regulates the stability and availability of β-catenin, thus playing a key role in the modulation of the Wnt signaling cascade. Wnt/β-catenin signaling initiates by binding of the Wnt protein to the Fz/LRP receptor complex (Figure 1, left panel). As soon as Wnt binds Fz and LPR, the destruction complex is deactivated. As a consequence, non-phosphorylated active β-catenin accumulates in the cytoplasm and it translocates into the nucleus where it binds to the lymphoid enhancer factor/T-cell factor (LEF/TCF). This binding displaces the transcriptional inhibitor Groucho, and in a complex with TCF initiates transcription of target genes such as CD44, EpCAM, survivin, cyclin D1, glutamine synthetase, iNOS, and c-Myc, among others[7,8,16-19]. In normal cells, extracellular Wnt ligands can interact with a few secreted antagonists, including frizzled-related protein and Dickkopf family members, preventing the activation of this pathway.

The association of Wnt pathway and carcinogenesis
was first described in patients with APC, where β-Catenin pathway is altered. Interestingly, many additional associations between components of this pathway and disease, including hepatocarcinogenesis, have been revealed over the last two decades.

WNT/β-CATENIN ACTIVATION IN HEPATOCARCINOGENESIS

Aberrant activation of Wnt/β-Catenin signaling has been reported in a wide range of HCC patients. Nuclear accumulation of β-catenin is strongly associated with β-catenin mutations, a majority of which have been described to be missense mutations at exon 3, responsible for phosphorylation and destruction of β-catenin.

Mutations in β-catenin gene 1 (CTNNB1) have been reported in around 20%-40% of all HCC cases. Cieply et al. compared the tumor features of HCC in the presence or absence of CTNNB1 gene mutations. Their results indicated a strong association between the presence of CTNNB1 mutations and increased tumor size, macrovascular and microvascular invasion, which supports the contribution of aberrant β-catenin signaling to tumor aggressiveness. The abnormal activity of β-catenin has been also linked with HCC in the setting of HCV and HBV infections. High incidence of CTNNB1 mutations in up to 40% of cases has been reported in patients with HCC and HCV infection. Previous studies have also correlated the presence of HCV core protein with increased expression of Wnt-1 in hepatoma cells.

Lachenmayer et al. proposed a molecular classification of HCC based on Wnt-pathway aberrations in HCC into two groups: CTNNB1 molecular class and Wnt-TGFβ molecular class. The authors found that Wnt-TGFβ class was associated with cytoplasmic β-catenin accumulation, vascular invasion, and an increased risk of early recurrence after surgical resection. A strong association between cytoplasmic β-catenin expression and poor histological differentiation, tumor size > 5 cm in diameter, and decreased disease-free survival has previously been reported. Inagawa et al. demonstrated poor prognosis in HCC patients with nuclear β-catenin accumulation in high grade HCC tumors. Nuclear β-catenin accumulation in HCC has also been associated to Ki67, suggesting that β-catenin promotes tumor proliferation and progression.

The link between Wnt/β-catenin signaling pathway and cell cycle seems to play a crucial role during the genesis and development of HCC. Wang et al. reported that suppressing β-catenin gene may induce the changes in cyclin B1 and cyclin C protein expression. Liu et al. showed that human zinc finger protein 191 is a potential regulator of the β-catenin transcription, found to be significantly overexpressed in human HCC specimens and associated with growth of human HCC cells. Mutations have also been reported in the components of the degradation complex of β-catenin including AXIN1 in around 3%-16% and AXIN2 in

Figure 1  Wnt-β-catenin signaling pathway. Binding of Wnt protein initiates a cascade, which results in activation of β-catenin, its accumulation in the cytoplasm and translocation into the nucleus to enhance the transcription of target genes (Left); When Fz/LRP receptors are not engaged, CK1 and GSK3B sequentially phosphorylate Axin-bound β-catenin. Consequently, β-catenin is ubiquitinated and targeted for rapid destruction by the proteasome (Right).
around 3% of all HCC cases\(^{33}\).

Three other Wnt genes (Wnt3, Wnt4 and Wnt5A), and three FZD genes (FZD3, FZD6 and FZD7) have been identified to be up-regulated in 60%-90% of human HCCs and more than 50% of the surrounding pre-neoplastic liver tissues, suggesting that their overexpression may be an early event in hepatocarcinogenesis\(^ {34}\).

Wnt/β-catenin signaling pathway has also been found to contribute to the regulation of HCC angiogenesis, infiltration, and metastasis through regulation of the expression of angiogenic factors such as MMP-2, MMP-9, VEGF-A, VEGF-C, and BFGF\(^ {35}\).

### MOLecular MecHAnisms of hCC

#### LCSC and β-catenin signaling

Hepatocarcinogenesis is a complex process that so far has not been completely elucidated. The Cancer Stem Cells (CSCs) hypothesis postulates that tumors are comprised of a heterogeneous population of cells, which includes a minor group of cells characterized by their capacity of continuous self-renewal and differentiation, long-lasting survival, and transplantability. It has been suggested that presence of LCSCs within the tumors could explain HCC heterogeneity, metastasis, recurrence, and chemotherapeutic resistance\(^ {36-39}\).

Different cell markers, including EpCAM, CD133, CD90, CD44, CD24, and CD13, have been used to identify the LCSC subpopulation. Such markers are heterogeneous in expression and represent cells of different origins. EpCAM, CD44, and CD133 are the most frequently used markers for the enrichment of tumor-initiating cells from primary human cancer\(^ {38-40}\). Yamashita et al\(^ {41}\) published that isolated HCC EpCAM\(^ +\) cells from alpha-fetoprotein positive HCC cases are LCSCs, in which activation of Wnt/β-catenin signaling is a major feature. Other reports suggest that pharmacologic targeting of β-catenin could inhibit proliferation and invasiveness capacity of LCSCs producing downregulation of the expression of markers (CD44 and CD133) in vitro and in vivo\(^ {42}\).

Our group and others have studied LCSCs and differences in resistance patterns with HCC cell lines (Huh7, Hep3B, PLC) in vitro and in vivo by targeting the Wnt/β-catenin pathway\(^ {43-45}\). Understanding the precise molecular basis of altered Wnt/β-catenin pathway should bring important advances in HCC biology with significant therapeutics associations.

#### MicroRNAs regulation of β-catenin pathway in HCC

Emerging evidence suggests the role of microRNAs (miRNAs) in the regulation of key biological properties of LCSCs\(^ {46}\). During hepatocarcinogenesis miRNAs have been shown to have both tumor suppressive and oncogenic activity. Selected miRNAs such as miR-21, miR-224, miR-34a, miR-221/222, miR-106a, and miR-203, are upregulated in HCC\(^ {47}\).

Analyses of miRNA expression have shown the different level of expression of miR-122a, miR-125a, and miR-150 in HCC cells and normal human primary hepatocytes\(^ {48,49}\). Augello et al\(^ {50}\) studied the expression of 664 mature miRNA in a cohort of 60 HCV-positive liver lesions and determined the genomic status of the miRNA chromosome 19 miRNA cluster (C19MC). Four miRNAs overexpressed in HCC belonged to C19MC and were significantly associated with microvascular invasion. Ji et al\(^ {51}\) found that the reduced expression of miR-26 correlated with the development of more aggressive forms of HCC. Interestingly, the same authors found that the expression of miR-26 is an independent predictor of survival in HCC patients. miRNA-181 has been shown to regulate the Wnt/β-catenin signaling pathway in a positive feedback loop, promoting the stem cell-like features of HCC cells\(^ {52}\). Overall, the exploration of the molecular link between Wnt/β-catenin and miRNAs could increase the understanding of the intricate molecular regulation in LCSCs, facilitating the design of effective therapeutic strategies.

#### Targeting β-catenin pathway: Is there a role for combination therapy in HCC?

Sorafenib monotherapy is currently the standard of care for patients with advanced HCC\(^ {2,3}\). However, in a double-blind, placebo-controlled trial, the median overall survival of patients on sorafenib group is prolonged by only 2.8 mo\(^ {53}\). Therefore, there is a particular interest in the development of new and more effective strategies to treat HCC. Evidence from in vitro and in vivo studies indicates that combination therapy could be more effective. Our group has demonstrated additive and synergistic effect of targeting Ras/Raf/MAPK pathway in combination with other pathways important in HCC proliferation such as PI3K/AKT/mTOR and Wnt/β-catenin\(^ {55}\).

Based on recent studies indicating the important role of Wnt/β-catenin signaling in the maintenance of CSCs, there has been increasing interest in developing new compounds to inhibit this pathway (Tables 1 and 2). One of the first studies aimed at disrupting the interaction between β-catenin and TCF. About 7000 natural compounds were screened using an enzyme-linked immunosorbent assay\(^ {54}\). Two fungal-derived compounds, PKF115-854 and CGP04909, showed the best results for their potency and specificity in antagonize the β-catenin-mediated cellular effects\(^ {54}\). These compounds have been further tested as anticancer drugs for malignancies displaying frequent upregulation in the Wnt/β-catenin signaling such as human multiple myeloma\(^ {55}\), Acute Myelocytic Leukemia\(^ {56}\), Chronic Lymphocytic Leukemia\(^ {57}\) and HCC\(^ {58,59}\). Two studies have assayed the therapeutic potential of CGP049090, PKF115-584 and PKF118-310 in HCC. All three compounds showed dose-dependent cytotoxicity against HCC cells with relative lower cyto-
January 14, 2016 | Volume 22 | Issue 2

Table 1 Molecular therapies targeting Wnt/β-catenin pathway in hepatocellular carcinoma

| Compound          | Targets in vitro                                                                 | Target in vivo                                                                 |
|-------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Sorafenib         | Decrease of TCF/LEF, β-catenin protein levels and Wnt-target genes mRNA levels   | Decrease tumor volume and increase survival of treated animals in HepG2 xenografts in nude mice, Inhibitory effect in Huh7 xenografts |
| sFZD2             | Block interaction between FZD and Dvl. Decrease viability of HepG2, Hep40 and Huh7 cell lines. Reduced expression of c-Myc, Cyclin D1 and Survivin. The effect was potentiated in combination with Doxorubicin | Inhibitory effect in Huh7 xenografts |
| RHPDs             | Decrease viability of human HCC cell lines (Huh7 and HepG2) through degradation of β-catenin and activation of PKCδ in a TP53-independent manner | Intratumor injection in SV40-TAg transgenic mouse model induced HCC progression |
| BrMC              | Inhibition of CD133+ LCSCs proliferation, EMT and invasion in MHCC97 cell line, and decreased expression of beta-catenin in this LCSCs | Inhibition of LCSCs proliferation in Balb/c-ruu mice xenografts model |
| SL1122-375(S) (Sorafenib derivative) | Inhibitory effect on the proliferation of HCC PLC/PRF/5 cells and the formation of angiogenesis of HUVEC(2) | Decrease of Wnt signaling in transgenic zebrafish |
| PMED-1            | Blocks β-catenin and CBF interaction. Suppression of downstream effects in β-catenin signaling in HCC cell lines | Inhibited growth of HepG2 xenograft model of HCC, Reduce tumor growth in a conditional APC mutant mouse model of colon cancer, Repressed lung cancer formation in murine xenografts and transgenic syngeneic lung cancer models |
| XAV939            | Inhibit Tankyrase 1 and 2 inducing degradation of β-catenin by stabilization of Axin. Antitumor activity against neuroblastoma (67), colon (68), breast (69) and lung (70) cancers, and HCC Decreased nuclear β-catenin levels, cell proliferation and colony formation in HepG2 and Huh7 | Inhibitory effect in murine xenograft model of human MM3, HepG2 xenograft model of HCC, JVM-3 subcutaneous xenograft model of CCL |
| CGP049090         | Block TCF/LEF and β-catenin interaction. Decrease expression of c-myc, Cyclin D1 and Survivin in AML1(58), CCL(57), MM(60) and HCC(69,70) | Inhibitory effect in murine xenograft model of human MM3, HepG2 xenograft model of HCC, JVM-3 subcutaneous xenograft model of CCL |
| PKF115-844        | Cells. Induced apoptosis and cell cycle arrest at the G1/S phase. Inhibition of the activation of β-catenin-regulated genes in the HCC cell lines Huh7, Hep3B and PLC and LCSC. Arrests the cell cycle from G1 to S-phase | Inhibitory effect in murine xenograft model of human MM3, HepG2 xenograft model of HCC, JVM-3 subcutaneous xenograft model of CCL |
| PKF118-310        | Synergistic inhibition of LCSC and Huh7 cell lines proliferation. Dose dependent inhibition of Cyclin D1, Survivin and Bcl2 expression | Inhibitory effect in murine xenograft model of human MM3, HepG2 xenograft model of HCC, JVM-3 subcutaneous xenograft model of CCL |
| FH535             | Synergistic inhibition of LCSC and Huh7 cell lines proliferation. Dose dependent inhibition of Cyclin D1, Survivin and Bcl2 expression | Inhibitory effect in murine xenograft model of human MM3, HepG2 xenograft model of HCC, JVM-3 subcutaneous xenograft model of CCL |
| FH535 and Sorafenib combination | Synergistic inhibition of LCSC and Huh7 cell lines proliferation. Dose dependent inhibition of Cyclin D1, Survivin and Bcl2 expression | Inhibitory effect in murine xenograft model of human MM3, HepG2 xenograft model of HCC, JVM-3 subcutaneous xenograft model of CCL |

LEF/TCF: Lymphoid enhancer factor/T-cell factor; HCC: Hepatocellular carcinoma; LCSCs: Liver cancer stem cells.

toxicity to normal hepatocytes. In a HepG2 xenograft model, these compounds inhibited tumor growth associated with apoptosis and reduced levels of TCF4/β-catenin target genes (48). Yamashita et al (59) demonstrated that the epithelial cell adhesion molecule (EpCAM, a hepatic stem cell marker) is a direct transcriptional target of the Wnt/β-catenin pathway in HCC. EpCAM-expressing HCC were more sensitive to the EPAM-expressing HCC. Thorne et al (60) identified the FDA-authorized drug Pyrvinium as an inhibitor of the Wnt signaling by enhancing the activity of the destruction complex though the binding to CK1 and selectively potentiating CK1δ kinase activity. Whereas protein kinases have proven to be effective drug targets in cancer, the specific role of inhibitors of CK1 have yet to be completely elucidated.

Other low molecular mass compounds such as XAV939 have been identified to prolong the half-life of Axin and promote β-Catenin degradation through inhibiting tankyrase.

Other strategy for attenuating the Wnt/β-catenin signaling pathway is by blocking the interaction between Fz receptors with their ligands. The effective interference of Fz and Wnt interaction has been achieved with monoclonal antibodies or with recombinant soluble fragment of Fz (sFz). OMP-18RS, is a novel monoclonal antibody that interacts with five Fz receptors to block canonical Wnt signaling. It has been used to inhibit the growth of several types of human cancers and has shown to be synergistic with other drugs such as taxol, irinotecan and gemcitabine.

Wei et al (61) found that a recombinant sFz7 peptide inhibited Wnt/β-Catenin signaling and decreased proliferation and tumorigenesis in some HCC cell lines. Nambotin et al (62) used small interfering peptides in HCC to block Fz7 function Wnt signaling and tumor progression.

Chrysin, a naturally distributed flavonoid, has been described to inhibit proliferation and induce apoptosis in a variety of cancer cells (63). Quan et al (42) demonstrated that a synthetic analogue of Chrysin, 8-bromo-7-methoxychrysin, inhibited the stem cell-like properties of CD133+ cells derived from MHCC97 cell line in vivo and in vitro. They proposed that the mechanism may relate to a reduction levels of Akt and activation of GSK-3β (64).

Interestingly, some small molecules that inhibit the interaction between β-Catenin and CBF could induce cancer stem cells to differentiate, thereby eventually clearing the pool of cancer initiating cells.

Delgado et al (65) identified a small molecule inhibitor of β-catenin PMED-1 that blocks β-catenin signaling and β-catenin-CBP interactions in multiple cells lines (Hep3B, HepG2, Snu-398 and Snu-449), reducing...
Table 2 Percentage inhibition of [3H]-thymidine incorporation in Huh-7 cells by FH535 analogs

| FH535 analog | C-2 | C-3 | C-4 | C-5 | C-6 | C-2' | C-3' | C-4' | C-5' | C-6' | % Inhibition at 10 µmol/L | Ratio of % inhibition of analog to % inhibition by FH535 at 10 µmol/L | TOPFlash Assay (10 µmol/L) | TOPFlash Assay as a Percentage Decrease Relative to Control |
|--------------|-----|-----|-----|-----|-----|------|------|------|------|------|-----------------------------|------------------------------------------------------------------------|-----------------------------|----------------------------------------------------------|
| Control      |     |     |     |     |     |      |      |      |      |      | 100 ± 10                    |                                                                        | 31.2 ± 4.5                  | 73                                                        |
| 1a           | Cl  |     | Cl  |     | Cl  |     |     |     |     |     | 64 ± 3.7                      | 36                                                                      | 10                          | 85 ± 2.1                   | 61                                                        |
| 1b           | Cl  |     | Cl  |     | Cl  |     |     |     |     |     | 82 ± 4.2                      | 18                                                                      | 0.5                        | 61                                                        |
| 1c           | Cl  | Cl  | H   | Cl  | H   |     |     |     |     |     | 103 ± 5.6                     | 7                                                                       | 0.2                        | 61                                                        |
| 1d           | Cl  | Cl  | Cl  | Cl  | Cl  |     |     |     |     |     | 106 ± 14                      | 0                                                                        | 0.0                        | 61                                                        |
| 1e           | Cl  | Cl  | Cl  | Cl  | Cl  |     | Cl  |     |     |     | 33 ± 4.8                      | 67                                                                      | 1.9                        | 61                                                        |
| 1f           | Cl  | Cl  | Cl  | Cl  | Cl  | 1-(4-N02)C6H      |     |     |     |     | 52 ± 6.4                      | 48                                                                      | 1.3                        | 61                                                        |
| 1g           | Cl  | Cl  | Cl  | Cl  | Cl  |     |     |     |     |     | 71 ± 1                        | 29                                                                      | 0.8                        | 13                                                        |
| 1h           | Cl  | Cl  | Cl  | Cl  | Cl  |     |     |     |     |     | 27 ± 5.3                      | 73                                                                      | 2.0                        | 13                                                        |
| 1i           | F   | H   | H   | F   | H   |     |     |     |     |     | 62 ± 1.5                      | 36                                                                      | 1.1                        | 13                                                        |
| 1j           | H   | H   | H   | H   | Cl  |     |     |     |     |     | 47 ± 2.3                      | 53                                                                      | 1.5                        | 13                                                        |
| 1k           | F   | H   | H   | F   | H   |     |     |     |     |     | 66 ± 3.2                      | 34                                                                      | 0.9                        | 13                                                        |
| 1l           | F   | H   | H   | F   | H   | OCH3H   | H   | H   |     |     | 57 ± 2.1                      | 43                                                                      | 1.2                        | 13                                                        |
| 1m           | F   | H   | H   | F   | H   |     |     |     |     |     | 67 ± 12                       | 33                                                                      | 0.9                        | 13                                                        |
| 1n           | F   | H   | H   | F   | H   | 1-(4-N02)C10H     |     |     |     |     | 69 ± 3.31                     | 31                                                                      | 0.9                        | 64                                                        |
| 1o           | Cl  | Cl  | Cl  | Cl  | Cl  | OCH3H   | H   | H   |     |     | 62 ± 10                       | 38                                                                      | 1.1                        | 45                                                        |
| 1p           | Cl  | Cl  | Cl  | Cl  | Cl  | OCH3H   | H   | H   |     |     | 69 ± 6.9                      | 31                                                                      | 0.9                        | 53                                                        |
| 1q           | F   | H   | H   | F   | H   |     |     |     |     |     | 67 ± 5.9                      | 33                                                                      | 0.9                        | 53                                                        |
| 1r           | Cl  | Cl  | Cl  | Cl  | Cl  | 1-(4-N02)C6H     |     |     |     |     | 74 ± 2.7                      | 26                                                                      | 0.7                        | 47                                                        |
| 1s           | H   | H   | H   | H   | H   |     |     |     |     |     | 71 ± 12                       | 29                                                                      | 0.8                        | 47                                                        |
| 1t           | H   | H   | H   | H   | H   |     |     |     |     |     | 62 ± 2.3                      | 38                                                                      | 1.1                        | 47                                                        |
| 1u           | H   | H   | H   | H   | H   | 1-(4-N02)C6H     |     |     |     |     | 58 ± 6.9                      | 42                                                                      | 1.2                        | 47                                                        |

From Kriete et al. with permission of Bioorg Med Chem Lett.

Sorafenib has also been investigated as a potential Wnt modulator in experimental models. Lachenmayer et al. found that Sorafenib reduced Wnt signaling and β-catenin expression in different cell lines in vitro and, in a xenograft model, xenograft nude mice treated with Sorafenib showed reduced HepG2 tumor growth. The small molecular agent FH535 has been shown to inhibit proliferation of HCC and hepatoblastoma cell lines. Liu et al. also reported that this antiproliferative effect was associated with the reduced expression of β-catenin INOS.

Our group studied the effects of combined therapy targeting Ras/Raf/MAPK and Wnt/β-catenin over HCC and LCSCs proliferation. We found that FH535 in combination with sorafenib caused synergistic inhibition of proliferation in both tumor cell types (Figure 2). FH535 demonstrated a dose-dependent inhibition of Cyclin D1, Survivin, Bcl2 and c-Myc expression. It was found that co-transfected wild-type β-catenin expression vector increased nearly 15-fold the luciferase activity from TOPFlash reporter assay compared to cells co-transfected with the empty vector control. We have also identified the FH535-mediated inhibition of β-Catenin-dependent gene expression in HCC cells. Our group has compared the activities induced by of XAV939 and FH535 on LCSCs and non-LCSC lines. Our results suggest that β-catenin/TCF/LEF inhibition site of FH535 may directly target the transcription promoter site. Further studies will determine the effects associated with FH535 ability to inhibit PPAR and to address the toxicity and efficacy for the treatment of HCC. Due to favorable results obtained using this compound alone and in combination with Sorafenib, our laboratory has recently developed an array of FH535 derivatives, some of which display a potent and selective β-catenin inhibitory activity in HCC cells.

their viability and proliferation on a transient mode. However, a major drawback of this study was the lack of in vivo studies in xenograft models due to the hydrophobic nature and relatively short half-life of PMED-1. It was found that co-transfected wild-type β-catenin expression vector increased nearly 15-fold the luciferase activity from TOPFlash reporter assay compared to cells co-transfected with the empty vector control. The FH535-mediated inhibition of β-Catenin-dependent gene expression in HCC cells. Our group has compared the activities induced by of XAV939 and FH535 on LCSCs and non-LCSC lines. Our results suggest that β-catenin/TCF/LEF inhibition site of FH535 may directly target the transcription promoter site. Further studies will determine the effects associated with FH535 ability to inhibit PPAR and to address the toxicity and efficacy for the treatment of HCC. Due to favorable results obtained using this compound alone and in combination with Sorafenib, our laboratory has recently developed an array of FH535 derivatives, some of which display a potent and selective β-catenin inhibitory activity in HCC cells.
To date, there are two ongoing clinical phase I/II trials using compounds such as PRI-724 and OMP-18R5 targeting β-catenin signaling pathway for the treatment of solid tumors and myeloid malignancies, suggesting the potential use of β-catenin inhibition in the treatment of HCC.

CONCLUSION

The molecular mechanisms of early liver transformation in carcinogenesis are poorly elucidated. Hepatocarcinogenesis is a complex multistep process where tumors originate from either LCSC or mature hepatocytes, and the tissue undergoes chronic inflammation, apoptosis, unrestricted proliferation, and permanent liver remodeling. An ideal drug regimen would eliminate specifically different cancer cells, including those with stem cell properties. Combined therapy may be necessary to overcome the complex network of signaling pathways and ultimately inhibit the signaling events that control tumor growth and survival. So far it remains unclear the specific Wnt-targets and downstream signals that contribute to Wnt signaling diversity on liver cancer. Evidence suggests that this pathway represents an important molecular target for HCC therapy as its mutation and activation are intrinsically involved with tumor initiation and development in at least one-third of HCC.

The increasing knowledge on adult stem cell biology and the general acceptance of the LCSCs hypothesis promise to bring revolutionary advances to HCC therapy. In this context, no effective compounds targeting β-catenin are yet approved for clinical use, but further investigation should be granted to identify selective inhibitors of this pathway and better define their efficacy and toxicity with the ultimate goal to be used either alone or in combination to treat patient with advanced HCC.

REFERENCES

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1]
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]
3. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327 [PMID: 18821591 DOI: 10.1002/hep.22506]
4. Galuppo R, Gedaly R. Synergistic inhibition of HCC and liver cancer stem cell modulation by sorafenib. Oncogene 2009; 28: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0908857]
5. Kudo M. Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol 2010; 15: 242-255 [PMID: 20509038 DOI: 10.1007/s10147-010-0089-y]
6. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006; 25: 3778-3786 [PMID: 16799619 DOI: 10.1038/sj.onc.1209547]
7. Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 2011; 21: 44-58 [PMID: 21182948 DOI: 10.1016/j.semcancer.2010.12.010]
8. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012; 149: 1192-1205 [PMID: 22682243 DOI: 10.1016/j.cell.2012.05.012]
9. Lee HC, Kim M, Wands JR. Wnt/β-catenin signal transduction in hepatocellular carcinoma. Front Biosci 2006; 11: 1901-1915 [PMID: 16368566]
10. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24 [PMID: 12781368]
11. Lachenmayer A, Alsinet C, Savic R, Cabelllos L, Toffanin S, Hoshida Y, Villanueva A, Minguex B, Newell P, Tsai HW, Barretina J, Thang S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012; 18: 4997-5007 [PMID: 22811581 DOI: 10.1158/1078-0432.CCR-11-2322]
12. Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, Gedaly R. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin.
Wnt/β-catenin pathway in HCC therapy

Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. *Am J Pathol* 1999; 155: 703-710 [PMID: 10487827]

31 Wang B, Xunsun JY, Yang D, Yang LK, Kong DX, Meng XW. The effect of cell cycle and expression of cyclin B1 and cyclin C protein in hepatocellular carcinoma cell line HepG2 and SMMC-7721 after of silencing β-catenin gene. *Hepatogastroenterology* 2012; 59: 515-518 [PMID: 22024040 DOI: 10.5754/hge.11534]

32 Liu G, Jiang S, Wang C, Jiang W, Liu Z, Liu C, Saiyim H, Yang X, Shen S, Jiang D, Zhou P, Han D, Hu X, Yi Q, Yu L. Zinc finger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma. *Hepatology* 2012; 55: 1830-1839 [PMID: 22213192 DOI: 10.1002/hep.25564]

33 Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA, Liu W. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. *Oncogene* 2002; 21: 4863-4871 [DOI: 10.1038/sj.onc.1205951]

34 Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy C, Longerich T, Schirmacher P. Dysregulation of Wnt-β-catenin signaling pathways. *Future Oncol* 2013; 29: 143-150 [PMID: 18577996 DOI: 10.2217/14796694.9.6.647]

35 Qu B, Liu BR, DU YJ, Chen J, Cheng YQ, Xu W, Wang XH. Wnt/β-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma. *Oncol Lett* 2014; 7: 1175-1178 [PMID: 24044688 DOI: 10.3892/ol.2014.1828]

36 Ji J, Wang WX. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. *Semin Oncol* 2012; 39: 461-472 [PMID: 22846863 DOI: 10.1053/j.seminoncol.2012.05.011]

37 Takahashi-Yanaga F, Kain H. Targeting Wnt signaling: can we safely eradicate cancer stem cells? *Clin Cancer Res* 2010; 16: 3153-3162 [PMID: 20536097 DOI: 10.1186/1742-1241.2013.4863]

38 Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical significance of the stem cell marker CD90+ in hepatocellular carcinoma. *Oncogene* 2012; 31: 11851-11858 [PMID: 10487827]

39 Salashor J, Moon RF. WNT signalling pathways as therapeutic targets in cancer. *Nat Rev Cancer* 2013; 13: 11-26 [PMID: 23258166 DOI: 10.1038/nrc3419]

40 Anastas JS, Moon RF. WNT signalling pathways as therapeutic targets in cancer. *Nat Rev Cancer* 2013; 13: 11-26 [PMID: 23258166 DOI: 10.1038/nrc3419]

41 Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in β-catenin gene. *Hepatology* 2009; 49: 821-831 [PMID: 19101982 DOI: 10.1002/hep.22695]

42 Wong CM, Fan ST, Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. *Cancer* 2001; 92: 136-145 [PMID: 11443619]

43 Inagawa S, Itabashi M, Adachi S, Kawamoto T, Horii M, Shimazaki J, Yoshimi F, Fukao K. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. *Clin Cancer Res* 2002; 8: 450-456 [PMID: 11839663]

44 Nihet JT, Renard CA, Wei Y, Cherqui D, Zafrañi ES, Buendia MA.
Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fielt M, Thung S, Alisret C, Tovar V, Mazzaferrro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM.

Ras pathway activation in hepatocellular carcinoma and anti-tumor effect of combined sorafenib and ramapycin in vivo. *J Hepatol* 2009; 51: 725-733 [PMID: 19665249 DOI: 10.1016/j.jhep.2009.03.028]

Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer* 2006; 6: 857-866 [PMID: 17066945 DOI: 10.1038/nrc1997]

Chen XM, Lu Y, Yang R, Yang Z, Wang Q, Wu F. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/beta-catenin pathway. *Liver Int* 2012; 32: 752-760 [PMID: 22726899 DOI: 10.1111/j.1478-3231.2011.02795.x]

Angello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncali M, Bosari S. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. *Liver Int* 2012; 32: 772-782 [PMID: 22429613 DOI: 10.1111/j.1478-3231.2012.02795.x]

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambbs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. *N Engl J Med* 2009; 361: 1437-1447 [PMID: 19812400 DOI: 10.1056/NEJMoa0901283]

Ji J, Yamashita T, Wang XW. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. *Cell Biosci* 2011; 1: [PMID: 21171587 DOI: 10.1186/2045-3701-1-4]

Gedaly R, Angulo P, Hundle J, Daily MF, Chen C, Koch A, Evers BM. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MEK and PI3K/AKT/mTOR pathways. *Anticancer Res* 2010; 30: 4951-4958 [PMID: 21187475]

Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Merle P. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. *J Hepatol* 2011; 54: 288-299 [PMID: 21055837 DOI: 10.1016/j.jhep.2010.06.033]

Khou BY, Chua SL, Balunova P. Apoptotic effects of chrysin in human cancer cell lines. *Int J Mol Sci* 2010; 11: 2188-2199 [PMID: 20559509 DOI: 10.3390/ijms11052188]

Handeli S, Jonnal gard M, Axelrod F, Bond CJ, Cain J, Chartier C, Donijan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J, Hoey T. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. *Proc Natl Acad Sci USA* 2012; 109: 11717-11722 [PMID: 22753465 DOI: 10.1073/pnas.1106008109]

Wei W, Chua MS, Grepper S, So SK. Soluble Frizzled-7 receptor inhibitor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. *Mol Cancer* 2011; 10: 16 [PMID: 21314951 DOI: 10.1186/1476-4598-10-16]

Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, Kim M, Wands JR, Chevallier M, Jalinot P, Scoazec JY, Trepo C, Zoulam F, Merle P. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. *J Hepatol* 2011; 54: 288-299 [PMID: 21055837 DOI: 10.1016/j.jhep.2010.06.033]

Krill LM, Vilchez V, Jiang J, Turcios L, Chen C, Sviripa VM, Zhang W, Liu C, Spear B, Wart DS, Gedaly R.N-Aryl benzenesulfonamide inhibitors of [3H]-thymidine incorporation and beta-catenin signaling in human hepatocyte-derived Huh-7 carcinoma cells. *Bioorg Med Chem Lett* 2015; 25: 3897-3899 [PMID: 26243371 DOI: 10.1016/j.bmcl.2015.07.040]

Qin Y, Lu Y, Wang R, Li W, Qu X, SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis. *Bioorg Med Chem Lett* 2013; 23: 237-244 [PMID: 24284174]

Tian XH, Hou WJ, Fang Y, Fan J, Tong H, Bai SL, Chen Q, Xu H, Li Y. XAV939, a tankyrase 1 inhibitor, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/beta-catenin pathway. *Mol Cancer Ther* 2013; 12: 100 [PMID: 24308872 DOI: 10.1158/1535-7163.MCT-12-0631]
decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. *Cancer Res* 2012; 72: 2822-2832 [PMID: 22440753 DOI: 10.1158/0008-5472.CAN-11-3336]

74 **Bao R**, Christova T, Song S, Angers S, Yan X, Attisano L. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. *PLoS One* 2012; 7: e48670 [PMID: 23144924 DOI: 10.1371/journal.pone.0048670]

75 **Busch AM**, Johnson KC, Stan RV, Sanglikar A, Ahmed Y, Dmitrovsky E, Freemantle SJ. Evidence for tankyrases as antineoplastic targets in lung cancer. *BMC Cancer* 2013; 13: 211 [PMID: 23621985 DOI: 10.1186/1471-2407-13-211]

76 **Ma L**, Wang X, Jia T, Wei W, Chua MS, So S. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells. *Oncotarget* 2015; 6: 25390-25401 [PMID: 26246473 DOI: 10.18632/oncotarget.4455]
